Search results
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Market Watch· 21 hours agoMerck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-cancer patients because the study was likely to ...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga via Yahoo Finance· 15 hours agoThe trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab)...
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 16 hours agoThe study was testing whether a combination of the company’s flagship cancer drug Keytruda and its...
Merck’s trial of KEYTRUDA regimen fails to meet primary endpoint
Clinical Trials Arena via Yahoo Finance· 4 days agoMerck has announced that its Phase III KEYNOTE-B21 (ENGOT-en11/GOG-3053) clinical trial of KEYTRUDA...
...Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab)...
Benzinga· 3 hours agoOSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that
Merck stops skin cancer combination therapy testing in late-stage study
Reuters· 21 hours ago, opens new tab has discontinued testing a combination of an experimental antibody-based drug and...
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters via Yahoo News· 21 hours agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new...
Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint
Morningstar· 5 days agoMerck was hit with a setback in its efforts to expand its blockbuster cancer immunotherapy Keytruda after a late-stage study of its use in combination with chemotherapy to ...
Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations
FierceBiotech· 20 hours agoMerck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high...
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Zacks via Yahoo Finance· 17 hours agoBristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails...